HDAC Inhibitor Sodium Butyrate Augments the MEF2C Enhancement of Nampt Expression under Hypoxia

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|11|1604-1613

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.11, 2014-04, pp. : 1604-1613

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Changing Face of HDAC Inhibitor Depsipeptide

By  

Current Cancer Drug Targets, Vol. 9, Iss. 1, 2009-02 ,pp. : 91-100

Bentham Science Publishers

Access to resources Recommend Favorite

l-carnosine and verapamil inhibit hypoxia-induced expression of hypoxia inducible factor (HIF-1 α) in H9c2 cardiomyoblasts

By Bharadwaj L.A.   Davies G.F.   Xavier I.J.   Ovsenek N.  

Pharmacological Research, Vol. 45, Iss. 3, 2002-03 ,pp. : 175-181

Academic Press

Access to resources Recommend Favorite

Increasing Bcl-2 and Neuroglubin Expression in Hypoxic Hippocampal Neurons under Hypoxia Preconditioning and in 3-n-butylphalide Treated Cells under Oxygen Glucose Deprivation/Reoxygenation

By  

Clinical Immunology, Endocrine & Metabolic Drugs, Vol. 2, Iss. 1, 2015-06 ,pp. : 27-34

Bentham Science Publishers

Access to resources Recommend Favorite

Curcumin: A Natural Pan-HDAC Inhibitor in Cancer

By  

Current Pharmaceutical Design, Vol. 24, Iss. 2, 2018-04 ,pp. : 123-129

Bentham Science Publishers

Access to resources Recommend Favorite

Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer

By  

Current Drug Targets, Vol. 15, Iss. 6, 2014-06 ,pp. : 622-634

Bentham Science Publishers

Access to resources Recommend Favorite